Our aim is to be a leading international centre for MND, engaging with national and international partners and the UK’s leading centre for multidisciplinary training of basic and clinical scientists in MND. UCL Queen Square Institute of Neurology (IoN) has significant research and clinical expertise in Motor Neuron Disorders, including Amyotrophic lateral sclerosis (ALS) and Kennedy’s Disease (KD; also known as Spinal Bulbar Muscular Atrophy - SBMA).
About the Centre
UCL Queen Square Institute of Neurology (IoN) has significant research and clinical expertise in Motor Neuron Disorders
MND Clinical Service
The service has evolved over 30 years to provide a central referral point for all patients with Motor Neuron Disease.
Clinical Research
People referred to Queen Square Motor Neuron Disease Centre are offered the opportunity to contribute to ongoing clinical research in MND, Kennedy’s Disease (SBMA) and other neurological conditions.
Turning the Tide
Two years ago UCL and Crick Institute researchers made a crucial discovery about the causes of motor neuron disease/amyotrophic lateral sclerosis. This has led to a $100m investment aiming to translate these findings into a viable treatment for the disease. This film explains the exciting progress in developing the discovery, and how some MND patients are reacting to the news.
Global ALS Day
Researchers in the MND Centre created a short film for Global ALS Day (21st June), to illustrate what we do, how we do it, and why we do it. Please watch...
Contacts
Centre Coordinator: Debbie Hadley d.hadley@ucl.ac.uk
News
New insights into the treatment of ALS: MIROCALS clinical trial results published in The Lancet
Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published today in The Lancet.
12 May 2025
‘Healthy fats’ could protect against motor neurone disease
Enhancing levels of ‘healthy fats’ like omega-3s in the brain could be beneficial in motor neurone disease (MND) finds a new study in fruit flies and brain cells, led by UCL Queen Square Institute of Neurology researchers.
25 Feb 2025
UCL spinout launches with $101 million funding for motor neurone disease treatments
Trace Neuroscience, a UCL spinout biopharmaceutical company, has received $101m (£78m) in Series A funding, to help develop potential treatments for the most common form of motor neurone disease.
13 Nov 2024